Immunohistochemical study on topoisomerase IIα, Ki-67 and cytokeratin-19 in oral lichen planus lesions

Archives of Dermatological Research

Volumn 298, Issue 8, 2007, Pages 381-388

  Mattila, Riikka ^a   Alanen, Kalle ^b   Syrjänen, Stina ^a  

^a UNIVERSITY OF TURKU   (Finland)

^b UNIVERSITY OF TURKU   (Finland)

Author keywords

CK 19; DNA content; Ki 67; Oral lichen planus; Topoisomerase II

Indexed keywords

CYTOKERATIN 19; CYTOKERATIN ANTIBODY; DNA TOPOISOMERASE (ATP HYDROLYSING); DNA TOPOISOMERASE 2ALPHA; KI 67 ANTIGEN; MONOCLONAL ANTIBODY KI 67;

ADULT; AGED; ANEUPLOIDY; ANTIGEN EXPRESSION; APOPTOSIS; ARTICLE; ATROPHIC SKIN DISEASE; BASAL CELL; CANCER RISK; CELL COUNT; CELL HYPERPLASIA; CELL PROLIFERATION; CONTROLLED STUDY; DNA CONTENT; DYSPLASIA; FEMALE; FOLLOW UP; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INFLAMMATORY DISEASE; LICHEN PLANUS; MAJOR CLINICAL STUDY; MALE; MALIGNANT TRANSFORMATION; MICROARRAY ANALYSIS; MICROSCOPY; MOUTH ULCER; ORAL BIOPSY; PRIORITY JOURNAL; PROTEIN EXPRESSION; RISK FACTOR; SKIN BIOPSY; SKIN DEFECT;

ADULT; AGED; ANEUPLOIDY; ANTIGENS, NEOPLASM; BIOLOGICAL MARKERS; BIOPSY; CARCINOMA, SQUAMOUS CELL; CELL PROLIFERATION; DNA TOPOISOMERASES, TYPE II, EUKARYOTIC; DNA-BINDING PROTEINS; FEMALE; GENE EXPRESSION PROFILING; HUMANS; IMMUNOHISTOCHEMISTRY; KERATIN-19; KI-67 ANTIGEN; LICHEN PLANUS, ORAL; MALE; MIDDLE AGED; PRECANCEROUS CONDITIONS; SKIN NEOPLASMS;

EID: 33845509900     PISSN: 03403696     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00403-006-0711-z     Document Type: Article

References (34)

1. Akimitsu N, Kamura K, Tone S, Sakaguchi A, Kikuchi A, Hamamoto H, Sekimizu K (2003) Induction of apoptosis by depletion of DNA topoisomerase IIalpha in mammalian cells. Biochem Biophys Res Commun 307:301-307
2. Berger JM, Gamblin SJ, Harrison SC, Wang JC (1996) Structure and mechanism of DNA topoisomerase II. Nature 379:225-232
3. Bloor BK, Malik FK, Odell EW, Morgan PR (1999) Quantitative assessment of apoptosis in oral lichen planus. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 88:187-195
4. Brown DC, Gatter KC (1990) Monoclonal antibody Ki-67: its use in histopathology. Histopathology 17:489-503
5. Bruno S, Darzynkiewicz Z (1992) Cell cycle dependent expression and stability of the nuclear protein detected by Ki-67 antibody in HL-60 cells. Cell Prolif 25:31-40
6. Brustmann H, Naude S (2002) Expression of topoisomerase IIalpha, Ki-67, proliferating cell nuclear antigen, p53, and argyrophilic nucleolar organizer regions in vulvar squamous lesions. Gynecol Oncol 86:192-199
7. Davies L, Hardin NJ, Beatty BG (2006) Can Ki-67 predict recurrence of NO squamous cell carcinoma of the tongue? Ann Otol Rhinol Laryngol 115:12-17
8. Dissanayake U, Johnson NW, Warnakulasuriya KA (2003) Comparison of cell proliferation in the centre and advancing fronts of oral squamous cell carcinomas using Ki-67 index. Cell Prolif 36:255-264
9. Gibbons D, Fogt F, Kasznica J, Holden J, Nikulasson S (1997) Comparison of topoisomerase II alpha and MIB-1 expression in uterine cervical squamous lesions. Mod Pathol 10:409-413
10. Girod SC, Pfeiffer P, Ries J, Pape HD (1998) Proliferative activity and loss of function of tumour suppressor genes as 'biomarkers' in diagnosis and prognosis of benign and preneoplastic oral lesions and oral squamous cell carcinoma. Br J Oral Maxillofac Surg 36:252-260
11. Gonzalez-Moles MA, Caballero R, Rodriguez-Archilla A, Ruiz-Avila I, Bravo I (1996) Prognosis value of the expression of Ki-67 for squamous cell carcinoma of the oral cavity. Acta Stomatol Belg 93:159-165
12. Hafian H, Venteo L, Sukhanova A, Nabiev I, Lefevre B, Pluot M (2004) Immunohistochemical study of DNA topoisomerase I, DNA topoisomerase II alpha, p53, and Ki-67 in oral preneoplastic lesions and oral squamous cell carcinomas. Hum Pathol 35:745-751
13. Heck MM, Earnshaw WC (1986) Topoisomerase II: a specific marker for cell proliferation. J Cell Biol 103:2569-2581
14. Heck MM, Hittelman WN, Earnshaw WC (1988) Differential expression of DNA topoisomerases I and II during the eukaryotic cell cycle. Proc Natl Acad Sci USA 85:1086-1090
15. Jalava P, Kuopio T, Juntti-Patinen L, Kotkansalo T, Kronqvist P, Collan Y (2006) Ki67 immunohistochemistry: a valuable marker in prognostication but with a risk of misclassification: proliferation subgroups formed based on Ki67 immunoreactivity and standardized mitotic index. Histopathology 48:674-682
16. Lindberg K, Rheinwald JG (1989) Suprabasal 40 kd keratin (K19) expression as an immunohistologic marker of premalignancy in oral epithelium. Am J Pathol 134:89-98
17. Lynch BJ, Guinee DG, Jr. Holden JA (1997) Human DNA topoisomerase II-alpha: a new marker of cell proliferation in invasive breast cancer. Hum Pathol 28:1180-1188
18. Mattila R, Alanen K, Syrjanen S (2004) DNA content as a prognostic marker of oral lichen planus with a risk of cancer development. Anal Quant Cytol Histol 26:278-284
19. McPherson JP, Goldenberg GJ (1998) Induction of apoptosis by deregulated expression of DNA topoisomerase IIalpha. Cancer Res 58:4519-4524
20. Mirtti T, Kallajoki M, Aaltonen M, Alanen K (2001) Cyclin A and Ki-67 with DNA content in benign and malignant prostatic epithelial lesions. Anal Quant Cytol Histol 23:229-237
21. Moll R (1998) Cytokeratins as markers of differentiation in the diagnosis of epithelial tumors. Subcell Biochem 31:205-262
22. Nie M, Zhong L, Zeng G, Li B (2002) The changes of cytokeratin 19 during oral carcinogenesis. Zhonghua Kou Qiang Yi Xue Za Zhi 37:187-190
23. Raybaud H, Fortin A, Bairati I, Morency R, Monteil RA, Tetu B (2000) Nuclear DNA content, an adjunct to p53 and Ki-67 as a marker of resistance to radiation therapy in oral cavity and pharyngeal squamous cell carcinoma. Int J Oral Maxillofac Surg 29:36-41
24. Roland NJ, Caslin AW, Bowie GL, Jones AS (1994) Has the cellular proliferation marker Ki67 any clinical relevance in squamous cell carcinoma of the head and neck? Clin Otolaryngol 19:13-18
25. Ruutu M, Johansson B, Grenman R, Syrjanen S (2005) Two different global gene expression profiles in cancer cell lines established from etiologically different oral carcinomas. Oncol Rep 14:1511-1517
26. Scholzen T, Gerdes J (2000) The Ki-67 protein: from the known and the unknown. J Cell Physiol 182:311-322
27. Scully C, Beyli M, Ferreiro MC, Ficarra G, Gill Y, Griffiths M, Holmstrup P, Mutlu S, Porter S, Wray D (1998) Update on oral lichen planus: etiopathogenesis and management. Crit Rev Oral Biol Med 9:86-122
28. Stathopoulos GP, Kapranos N, Manolopoulos L, Papadimitriou C, Adamopoulos G (2000) Topoisomerase II alpha expression in squamous cell carcinomas of the head and neck. Anticancer Res 20:177-182
29. Taniguchi Y, Nagao T, Maeda H, Kameyama Y, Warnakulasuriya KA (2002) Epithelial cell proliferation in oral lichen planus. Cell Prolif 35 Suppl 1:103-109
30. van der Velden LA, Manni JJ, Ramaekers FC, Kuijpers W (1999) Expression of intermediate filament proteins in benign lesions of the oral mucosa. Eur Arch Otorhinolaryngol 256:514-519
31. Warnakulasuriya KA, Johnson NW (1996) Importance of proliferation markers in oral pathology. Curr Top Pathol 90:147-177
32. WHO World Health Organization Collaborating Centre for Oral Precancerous Lesions (1978) Definition of leukoplakia and related lesions; an aid to study precancer. Oral Surg Oral Med Oral Pathol 46:518-539
33. Willman JH, Holden JA (2000) Immunohistochemical staining for DNA topoisomerase II-alpha in benign, premalignant, and malignant lesions of the prostate. Prostate 42:280-286
34. Yoshida K, Yamaguchi T, Shinagawa H, Taira N, Nakayama KI, Miki Y (2006) Protein kinase C delta activates topoisomerase IIalpha to induce apoptotic cell death in response to DNA damage. Mol Cell Biol 26:3414-3431